Douglas A. Rubinson
0000-0002-5337-5231
Publication & Citation Trends
Most Cited Works
Publications
417 total
A Phase 2 Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2.
Cited by 0
Semantic Scholar
Clinical Implications of a Large-Scale Voluntary Preemptive DPYD Testing Program for Patients Planned for a Systemic Fluoropyrimidine: Preliminary Results.
Cited by 0
Semantic Scholar
Phase II trial of cabozantinib in combination with nivolumab for advanced extrapancreatic neuroendocrine tumors (epNET).
Cited by 0
Semantic Scholar
Abstract 1847: Closed-loop drug delivery system to personalize chemotherapy dosing
Cited by 0
Semantic Scholar
Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreatic Cancer.
Cited by 1
Semantic Scholar
Abstract B075: Young- and older-onset pancreatic cancers arise through distinct mechanisms: Insights from genomic and germline analyses
Cited by 0
Semantic Scholar
A phase II study of ramucirumab and somatostatin analog therapy in patients with advanced neuroendocrine tumors OA
Cited by 2
Semantic Scholar
Abstract A082: Distinct subsets of cytotoxic CD8 T cells delineate the rare pancreatic tumors that respond to PD-1 blockade
Cited by 0
Semantic Scholar
Research Topics
Pancreatic and Hepatic Oncology Research
(301)
Cancer Genomics and Diagnostics
(230)
Colorectal Cancer Treatments and Studies
(122)
Cancer Immunotherapy and Biomarkers
(44)
Immune cells in cancer
(34)
Frequent Co-Authors
Affiliations
Tufts University
Brigham and Women's Hospital
Howard Hughes Medical Institute
Harvard University
Eli Lilly (United States)